> For the complete documentation index, see [llms.txt](https://doc.duaer.com/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://doc.duaer.com/guides/pharmacovigilance-ai-agent-2027-first-pilot.md).

# Pharmacovigilance AI Agent 2027: Which Safety Workflow to Pilot First

This guide, compiled from the Duaer documentation site, explains how pharmacovigilance teams can choose the first workflow for an AI agent pilot, covering value and risk assessment, shadow-run design, escalation rules, and audit requirements.

## Why the first pharmacovigilance workflow is harder to choose

Pharmacovigilance teams sit at the intersection of high volume and zero tolerance for error. Adverse event reports arrive from spontaneous reporters, clinical trials, published literature, call centers, and increasingly from patient-facing channels. Each report must be received, checked for completeness, deduplicated, coded, assessed for causality, and submitted within regulatory deadlines. Headcount rarely keeps pace with case growth, so leadership asks whether an AI agent can take over part of this chain. The real difficulty is not a lack of ideas. It is choosing a first workflow where an agent can help without creating a hidden error that surfaces during an inspection or, worse, ends up in a patient record.

In most industries, a poor first pilot wastes budget. In drug safety, a poor first pilot can create regulatory exposure. Every output may eventually feed into a case file, a signal assessment, or a submission. The question therefore shifts from what the agent can do to what happens when it gets something wrong, and who will notice.

The second difficulty is that this work is a chain, not a set of isolated tasks. Intake depends on how reports are received. Deduplication depends on how narratives are written. Coding depends on the quality of the reporter's description. If an agent is inserted at the wrong point, it inherits upstream noise and passes errors downstream with a confident tone. Many teams only discover this after the pilot has already touched real cases.

The third difficulty comes from the data itself. Narratives are mostly free text, often incomplete, sometimes written in several languages, and frequently mix clinical detail with administrative clutter. An agent that performs well on a clean demonstration dataset can degrade sharply in the messy inbox a safety team actually works from.

## Common mistakes teams make

The most common mistake is starting with the most ambitious framing: fully autonomous end-to-end case processing. This sounds compelling in a steering committee, but it asks the agent to make decisions at every stage at once. When something goes wrong, no one can tell which stage caused it.

The second mistake is choosing signal detection because it sounds strategic. Signal work is valuable, but it depends on long, consistent historical data, clear ownership of statistical methods, and agreed escalation paths. A pilot that needs all of these on day one usually stalls.

The third mistake is measuring only speed. A pilot that doubles case closure rates but misses a small number of serious cases is not a success. Recall for serious and unexpected events matters most, and it is easy to overlook when dashboards celebrate throughput.

## Map workflows by value and risk, not enthusiasm

A practical approach is to list every candidate workflow on a single page and score each along two dimensions. The first is value: case volume, current cycle time, and how much reviewer time goes into repetitive steps. The second is risk: how much regulatory damage an error could cause, and whether the output can easily be reversed or reviewed.

In most safety teams, workflows in the high-value, low-risk quadrant include screening literature for relevant case reports, flagging possible duplicate reports for human confirmation, and checking intake forms for missing mandatory fields. Coding suggestions sit in the middle because they are useful but still need expert sign-off. Causality assessment and final regulatory submissions fall in the high-risk zone and should not be the first pilot.

This scoring is best tested against past cases rather than debated in meetings. Pull a sample of closed cases, see how the workflow would have performed, and count how often the agent's suggestion would have changed the final outcome. If your team wants to keep scoring and the first shadow test in one place, Duaer can help organize the candidate list, test sets, and review records so the comparison stays traceable. The same logic applies when choosing a vendor: define the workflow first, then evaluate providers against it. For a broader discussion of this sequencing, see [a guide to choosing AI pharma use cases before selecting a vendor](https://doc.duaer.com/guides/ai-pharma-companies/).

## Design the first pilot as a shadow run

The safest first deployment is usually a shadow run. The agent processes newly received or recently closed cases in parallel with human reviewers, but its outputs are not used for any decision. Each agent suggestion is compared with the human result, and disagreements are reviewed by a senior reviewer.

A shadow run needs a gold standard. Use a set of closed cases, ideally covering the past twelve months, labeled by experienced reviewers. Deliberately include difficult cases: multilingual narratives, cases with missing dates, and cases suspected of being duplicates that turned out to be independent events. An agent that only performs well on simple cases will not survive production.

Escalation rules must be written before the pilot starts. Any case flagged as serious, fatal, or potentially unexpected by either the reviewer or the agent should go to a human immediately, regardless of the agent's priority score. Under no circumstances should the agent become the only route by which a serious case is deprioritized. Put these rules into the standard operating procedure, and confirm that the agent cannot close or reclassify cases on its own during the pilot.

## Measure what regulators and QPPVs actually care about, and build in governance

A single accuracy figure hides the failures that matter. Split measurement into several parts. Recall for serious cases should be close to complete, and the threshold should be agreed with the Qualified Person for Pharmacovigilance (QPPV) before the pilot begins. Missed duplicates and wrongly flagged duplicates should be counted separately because they carry different risks. Measure reviewer time saved, but also measure rework, meaning how often humans have to reverse an agent's suggestion.

Regularly sample the agent's 'not relevant' or 'low priority' judgments. These are where silent failures live. Most teams review only positive results and ignore negatives, yet missed serious cases hide precisely there.

Finally, check the audit trail. For every agent output, you should be able to reconstruct the input, the model and prompt versions, the decision, and the person who accepted or overrode it. If you cannot answer what the system saw and produced on a given date, the pilot is not ready to leave shadow mode.

Pharmacovigilance data is highly sensitive, so the agent's runtime environment must stay within the controls your organization already applies to patient data. Version every prompt and model change, record who approved it, and update the standard operating procedure whenever the workflow changes. Treat model updates as changes to a validated process, not as routine software patches.

## What you can do this week

Choose one low-risk, high-volume candidate, typically intake completeness checks or literature screening. Extract two hundred closed cases from the past year. Have two experienced reviewers label them independently, then resolve disagreements in a short meeting. Next, let the agent process the same cases in shadow mode, and log every case where it disagrees with the reviewers, especially those it marked as low priority. This single exercise will tell you more about readiness than any vendor demonstration.

If you want to run this kind of shadow test without building the scoring sheet, test set, and review log from scratch, you can sign up at https://www.duaer.com and try the workflow there. Start with one workflow and one test set, and expand only after serious-case recall clearly meets the level your safety team can accept.

If you tell us which pharmacovigilance workflow you are considering, we can send you a written rollout path: https://api.duaer.com/form/c59a907a-3697-4edf-a04d-3ea0fb72fdc8

## Questions

### Which workflow should be the first AI agent pilot in pharmacovigilance?

Teams usually start with a high-volume, low-risk workflow such as intake completeness checks or literature screening, and avoid causality assessment or final regulatory submission at the outset. Before choosing, score candidates by value and risk, then validate them against closed cases from the past.

### What is a shadow run for pharmacovigilance AI, and how should it be designed?

A shadow run means the agent processes cases in parallel with human reviewers, but its outputs are not used for actual decisions. A good design includes an expert-labeled gold standard test set with difficult cases such as multilingual narratives and missing dates, a line-by-line comparison of agent suggestions with human results, and written escalation rules for serious cases agreed before the pilot starts.

### Which metrics matter most in a pharmacovigilance AI agent pilot?

Recall for serious and unexpected cases is the most important, with a threshold agreed in advance with the QPPV. Teams should also count missed and wrongly flagged duplicates separately, sample low-priority negative judgments, measure human rework, and keep an audit trail that lets them reconstruct each input, model version, decision, and reviewer.

